Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: An observational study using pooled European cohort data
HIV Medicine, Volume 16, No. 5, Year 2015
Notification
URL copied to clipboard!
Description
Objectives: This observational study in antiretroviral treatment-experienced, HIV-1-infected adults explored the efficacy of etravirine plus darunavir/ritonavir (DRV group; n=999) vs. etravirine plus an alternative boosted protease inhibitor (other PI group; n=116) using pooled European cohort data. Methods: Two international (EuroSIDA; EUResist Network) and five national (France, Italy, Spain, Switzerland and UK) cohorts provided data (collected in 2007-2012). Stratum-adjusted (for confounding factors) Mantel-Haenszel differences in virological responses (viral load < 50 HIV-1 RNA copies/mL) and odds ratios (ORs) with 95% confidence intervals (CIs) were derived. Results: Baseline characteristics were balanced between groups except for previous use of antiretrovirals (≥ 10: 63% in the DRV group vs. 49% in the other PI group), including previous use of at least three PIs (64% vs. 53%, respectively) and mean number of PI resistance mutations (2.3 vs. 1.9, respectively). Week 24 responses were 73% vs. 75% (observed) and 49% vs. 43% (missing=failure), respectively. Week 48 responses were 75% vs. 73% and 32% vs. 30%, respectively. All 95% CIs around unadjusted and adjusted differences encompassed 0 (difference in responses) or 1 (ORs). While ORs by cohort indicated heterogeneity in response, for pooled data the difference between unadjusted and adjusted for cohort ORs was small. Conclusions: These data do not indicate a difference in response between the DRV and other PI groups, although caution should be applied given the small size of the other PI group and the lack of randomization. This suggests that the efficacy and virology results from DUET can be extrapolated to a regimen of etravirine with a boosted PI other than darunavir/ritonavir. © 2015 British HIV Association.
Authors & Co-Authors
Vingerhoets, Johan H.
Belgium, Beerse
Janssen Pharmaceutica, Headquarters
Calvez, Vincent
France, Paris
Sorbonne Université
Flandre, Philippe
France, Paris
Sorbonne Université
Marcelin, Anne Geneviève
France, Paris
Sorbonne Université
Ceccherini-Silberstein, Francesca
Italy, Rome
Università Degli Studi Di Roma Tor Vergata
Perno, Carlo Federico
Italy, Rome
Università Degli Studi Di Roma Tor Vergata
Santoro, Maria Mercedes
Italy, Rome
Università Degli Studi Di Roma Tor Vergata
Nelson, Mark Richard
United Kingdom, London
Chelsea and Westminster Hospital
Cozzi-Lepri, Alessandro
Denmark, Copenhagen
Eurosida
Grarup, Jesper
Denmark, Copenhagen
Eurosida
Lundgren, Jens D.
Denmark, Copenhagen
Eurosida
Incardona, Francesca
Italy, Rome
Informa S.r.l.
Kaiser, Rolf
Germany, Koln
Universität zu Köln
Sönnerborg, Anders B.
Sweden, Stockholm
Karolinska Institutet
Clotet, Bonaventura
Spain, Barcelona
Fight Aids and Infectious Diseases Foundation
Paredes, Roger
Spain, Barcelona
Fight Aids and Infectious Diseases Foundation
Günthard, Hüldrych Fritz
Switzerland, Zurich
Universität Zürich
Ledergerber, Bruno
Switzerland, Zurich
Universität Zürich
Hoogstoel, Annemie
Belgium, Beerse
Janssen Pharmaceutica, Headquarters
Nijs, Steven
Belgium, Beerse
Janssen Pharmaceutica, Headquarters
Tambuyzer, Lotke
Belgium, Beerse
Janssen Pharmaceutica, Headquarters
Lavreys, Ludo
Belgium, Beerse
Janssen Pharmaceutica, Headquarters
Opsomer, Magda
Belgium, Beerse
Janssen Pharmaceutica, Headquarters
Statistics
Citations: 11
Authors: 23
Affiliations: 10
Identifiers
Doi:
10.1111/hiv.12218
ISSN:
14642662
Research Areas
Genetics And Genomics
Infectious Diseases
Study Design
Randomised Control Trial
Cohort Study